What We Do
We partner with large pharmaceutical companies, smaller biotech firms, and academic institutions to build our pipeline with promising investigational drugs in areas of significant unmet medical need.
We create new companies, which we call ‘Vants’, to develop and commercialize those drugs.
Finally, we support our Vants as they become leading companies in their therapeutic categories, while continuing to launch new Vants focused on making advances in additional areas.
Who We Are Today
Roivant was founded in May 2014. Today we have a team of several hundred staff members, a strong capital base with approximately $1.5 billion raised to date, and a pipeline of 14 drugs across our family of companies. At present our wholly- or majority-owned subsidiary companies include Axovant, Myovant, Dermavant, Enzyvant, and Urovant. And we’re just getting started.